Drugs / interleukin-2 gene
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00062036 | Jun 2003 → Feb 2007 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00006033 | Jun 2000 → Jun 2004 | head and neck cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002748 Background | Dec 1991 → Aug 2007 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-2 gene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002748 ↗ |